CRDF Stock Analysis: Buy, Sell, or Hold?
CRDF - Cardiff Oncology, Inc. Common Stock
$1.79
-0.05 (-2.72%)
▼
5d:
+3.47%
30d:
+3.47%
90d:
+11.18%
BUY
MODERATE Confidence
Analysis Updated: May 21, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When CRDF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
14 traders called CRDF this week
78% bullish • 6 bearish
78% bullish • 6 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRDF shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRDF shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRDF is currently trading at $1.79, which is considered extended relative to its 30-day fair value range of $1.63 to $1.75.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.60, while resistance sits at $1.99.
Market Sentiment: CRDF has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.69 (+329.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRDF is in a strong downtrend. Immediate support is located at $1.60, while resistance sits at $1.99.
Market Sentiment: CRDF has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.69 (+329.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.63 -
$1.75
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 329.5% below Wall St target ($7.69)
Trading Range Analysis
30-Day Trading Range
$1.63 -
$1.75
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.61
Resistance Level
$1.99
Current Trend
Strong Downtrend
Technical data as of
May 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.18
Wall Street Target
$7.69
(+329.5%)
Revenue Growth (YoY)
-62.4%
Share & Embed Analysis
Last updated: May 21, 2026 11:47 PM ET
Data refreshes hourly during market hours. Next update: 12:47 AM
Data refreshes hourly during market hours. Next update: 12:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRDF showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 64 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 52 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 62 BUY |
